Effectiveness of Rosuvastatin at Preventing the Progression of Atherosclerosis in HIV Positive Patients

• Status: Terminated
• Trial end date: 2013-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Rosuvastatin is a drug used to lower cholesterol, which also has other cardiovascular benefits. The goal of this project is to determine if rosuvastatin is effective at slowing the development of heart disease in people with HIV. We expect that after 2 years of treatment people treated with rosuvastatin will show significantly better results than people treated with a placebo.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of British Columbia
• Collaborators: AstraZeneca; CIHR Canadian HIV Trials Network
• Treatments: Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• HIV positive, at least one cardiovascular disease risk factor

Exclusion Criteria:

• Diabetes

• Previous vascular disease

• Muscular disease

• Current use of other lipid lowering therapy